Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis

Oncology

Volumn 72, Issue 3-4, 2008, Pages 188-193

  Ikeda, Masafumi ^a   Okusaka, Takuji ^a   Ueno, Hideki ^a   Morizane, Chigusa ^a   Iwasa, Satoru ^a   Hagihara, Atsushi ^a   Kojima, Yasushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Epirubicin; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Portal vein; Tumor thrombosis

Indexed keywords

EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEPATIC ARTERY; HUMAN; HYPOALBUMINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; NAUSEA; NEUTROPENIA; PORTAL VEIN; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR THROMBUS; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; EPIRUBICIN; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PORTAL VEIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VENOUS THROMBOSIS;

EID: 38549122890     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112805     Document Type: Article

References (23)

1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928.
2. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67.
3. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
4. Minagawa M, Makuuchi M: Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12:7561-7567.
5. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
7. Lencioni R, Cioni D, Crocetti L, Bartolozzi C: Percutaneous ablation of hepatocellular carcinoma: state-of-the-art (review). Liver Transpl 2004;10(2 suppl 1):S91-S97.
8. Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S179-S188.
9. Ishikura S, Ogino T, Furuse J, Satake M, Baba S, Kawashima M, Nihei K, Ito Y, Maru Y, Ikeda H: Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-193.
10. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25(suppl): 18S, abstract LBA1.
11. Okada S: Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 1998;45(suppl 3):1259-1263.
12. Ensminger WD, Gyves JW: Regional chemotherapy of neoplastic diseases. Pharmacol Ther 1983;21:277-293.
13. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK: Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999;46:1122-1125.
14. Aguayo A, Patt YZ: Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001;28:503-513.
15. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.
16. Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM: 4′-Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985;3:1535-1540.
17. Yoshikawa M, Saisho H, Ebara M, Iijima T, Iwama S, Endo F, Kimura M, Shimamura Y, Suzuki Y, Nakano T, et al: A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(suppl):S149-S152.
18. Nagasue N, Yukaya H, Okamura J, Kuroda C, Kubo Y, Hirai K, Tanikawa K, Okita K, Ando K, Tamura K: Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma (in Japanese). Gan To Kagaku Ryoho 1986;13:2786-2792.
19. Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai T, Deguchi M, Ohmori S, Nakano T: Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003;23:1719-1722.
20. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-595.
21. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005;93:557-564.
22. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106:1990-1997.
23. Schwartz JD, Schwartz M, Lehrer D, Cohen E, Sung M, Kinkhabwala M, Siegel A, Holloway S, Ocean A, Wadler S: Bevacizumab in unresectable hepatocellular carcinoma for patients without metastasis and without invasion of the portal vein. J Clin Oncol 2006;24(suppl):18s (abstract 4144).